Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

BACKGROUND: Patients with chromosome 5 abnormalities and high-risk myelodysplastic syndromes or acute myeloid leukemia have a poor outcome. We hypothesized that increasing doses of lenalidomide may benefit this group of patients by inhibiting the tumor clone, as assessed by fluorescence in situ hybr...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Möllgård, Lars, Saft, Leonie, Treppendahl, Marianne Bach, Dybedal, Ingunn, Nørgaard, Jan Maxwell, Astermark, Jan, Ejerblad, Elisabeth, Garelius, Hege, Dufva, Inge Høgh, Jansson, Monika, Jädersten, Martin, Kjeldsen, Lars, Linder, Olle, Nilsson, Lars, Vestergaard, Hanne, Porwit, Anna, Grønbæk, Kirsten, Lindberg, Eva Hellström
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Ferrata Storti Foundation 2011
विषय:
Original Articles
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3128214/
https://ncbi.nlm.nih.gov/pubmed/21719884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2010.039669
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन